COVID vaccine

A master phase protocol investigates the safety, tolerability and immunogenicity of a variant-adapted BNT 162b2 RNA-BASED vaccine in healthy children ages 6 months to 2 years old.
A master phase protocol investigates the safety, tolerability and immunogenicity of a variant-adapted BNT 162b2 RNA-BASED vaccine in healthy children ages 6 months to 2 years old.
2221 Peninsula Drive Erie, PA 16506
P: 814-838-8724
F: 814-835-5195
2017 © Square 1 Clinical Research
Powered by Epic Web Studios, LLC